Skip to main content
SpringerLink
Log in

Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent or Progressive Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome

  • Regional Cancer Therapies
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive disease for which cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been used with remarkable survival benefits. Our aim was to analyze the clinicopathologic characteristics and prognosis of recurrent DMPM managed with iterative CRS and HIPEC.

Methods

A retrospective analysis of a prospectively maintained database for all patients treated for DMPM from 1989 to 2012.

Results

Of 205 consecutive CRS and HIPEC procedures, 44 (21.5 %) patients underwent an iterative procedure—22 (50.0 %) males versus 22 (50.0 %) females. Mean age at recurrence was 51.5 years. There was no 30-day mortality following an iterative procedure, and the grade III–V morbidity was 2.3 %. The median overall survival of patients undergoing an iterative CRS and HIPEC was 54 months versus 77 months following an initial CRS and HIPEC (p = 0.96). Patients undergoing an iterative surgery had a 3- and 5-year survival of 61 and 46 %, respectively, versus 60 and 52 % following an initial CRS and HIPEC. Amongst the iterative group, the achieved complete cytoreduction (CC) score was 15.9, 18.2, 22.7, and 43.2 % for CC0, CC1, CC2 and CC3, respectively, versus 3.1, 43.5, 28.6 and 24.8 %, respectively, following initial CRS (p = 0.000). Significant predictors of an improved survival in multivariate analysis were an epithelioid subtype, female sex, complete or near CC (CC0 or CC1), HIPEC regimen utilized, absence of postoperative complication, and age at diagnosis.

Conclusion

Iterative CRS and HIPEC can be performed safely and appear to have benefits with this group of patients showing an improved median survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Tanida S, Kataoka H, Kubota E, et al. Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma. Int J Clin Oncol. 2009;14(3):266–9.

    Article  CAS  PubMed  Google Scholar 

  2. Scripcariu V, Dajbog E, Radu I, et al. Malignant peritoneal mesothelioma tumors: evolution, treatment, prognosis [in Romanian]. Rev Med Chir Soc Med Nat Iasi. 2007;111(3):673–7.

    CAS  PubMed  Google Scholar 

  3. Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14:41–9.

    Article  PubMed  Google Scholar 

  4. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Intengen ME. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma. J Surg Oncol. 1999;70:6–12.

    Article  CAS  PubMed  Google Scholar 

  5. Antman KH. Current concepts: malignant mesothelioma. N Engl J Med. 1980;303:200–2.

    Article  CAS  PubMed  Google Scholar 

  6. Antman KH, Osteen RT, Klegar KL, et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985;2(8462):977–81.

    Article  CAS  PubMed  Google Scholar 

  7. Turner K, Varghese S, Alexander HR. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Cancer. 2012;10:49–57.

    CAS  Google Scholar 

  8. Sugarbaker PH. Management of peritoneal-surface malignancy: the surgeon’s role. Arch Surg. 1999;384:576–87.

    Article  CAS  Google Scholar 

  9. Katz MH, Barone RM. The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am. 2003;12:673–88.

    Article  PubMed  Google Scholar 

  10. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689–701.

    Article  PubMed  Google Scholar 

  11. Feldman AL, Libutti JF, Pingpank DL, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7.

    Article  CAS  PubMed  Google Scholar 

  12. Sugarbaker P, Welch L, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am. 2003;12:605–21.

    Article  PubMed  Google Scholar 

  13. Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2006;13:229–37.

    Article  PubMed  Google Scholar 

  14. Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:686–691.

    Article  CAS  PubMed  Google Scholar 

  15. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg. 2001;67:999–1003.

    CAS  PubMed  Google Scholar 

  16. Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN, et al. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol. 2006;13:405–412.

    Article  CAS  PubMed  Google Scholar 

  17. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.

    Article  PubMed  Google Scholar 

  18. Nash G, Otis CN. Protocol for the examination of specimens from patients with malignant pleural mesothelioma: a basis for checklists. Cancer Committee, College of American Pathologists. Arch Pathol Lab Med. 1999;123:39–44.

    CAS  PubMed  Google Scholar 

  19. Yan T, Haveric N, Carmignani C, et al. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer. 2005;103:839–849.

    Article  PubMed  Google Scholar 

  20. Sugarbaker PH. An overview of peritonectomy, visceral resections, and perioperative chemotherapy for peritoneal surface malignancy. In: Sugarbaker PH (ed). Cytoreductive surgery and perioperative chemotherapy for peritoneal surface malignancy. Textbook and Video Atlas. Woodbury; Cine-Med; 2012: pp. 1–30.

    Google Scholar 

  21. Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, Figg WD, et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis. Cancer. 1998;83:1251–1261.

    Article  CAS  PubMed  Google Scholar 

  22. Chua TC, Quinn LE, Zhao J, Morris DL. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases. J Surg Oncol. 2013;108(2):81–8.

    Article  PubMed  Google Scholar 

  23. Votanopoulos K, Ihemelandu C, Shen P, et al. Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg. 2012;215(3):412–7.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori. 2003;89:269–73.

    PubMed  Google Scholar 

  25. Sugarbaker PH, Acherman YI, Gonzalez-Moreno S, et al. Diagnosis and treatment of peritoneal mesothelioma: the Washington Cancer Institute experience. Semin Oncol. 2002;29:51–61.

    Article  PubMed  Google Scholar 

  26. Chua TC, Esquivel J, Pelz JO, Morris DL. Summary of current therapeutic options for peritoneal metastases from colorectal cancer. J Surg Oncol. 2013;107(6):566–73.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Program in Peritoneal Surface Oncology, Washington Cancer Institute, Washington, DC, USA

    Chukwuemeka Ihemelandu MD, FACS, Lana Bijelic MD, FACS & Paul H. Sugarbaker MD, FACS, FRCS

Authors
  1. Chukwuemeka Ihemelandu MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lana Bijelic MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul H. Sugarbaker MD, FACS, FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chukwuemeka Ihemelandu MD, FACS.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ihemelandu, C., Bijelic, L. & Sugarbaker, P.H. Iterative Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent or Progressive Diffuse Malignant Peritoneal Mesothelioma: Clinicopathologic Characteristics and Survival Outcome. Ann Surg Oncol 22, 1680–1685 (2015). https://doi.org/10.1245/s10434-014-3977-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-3977-y

Keywords

Search

Navigation